NCT05048810View on ClinicalTrials.gov

Clinical Application of 68Ga-DOTA-NT-20.3 in the Early Diagnosis of Pancreatic Ductal Adenocarcinoma

NACompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

February 7, 2020

Primary Completion Date

March 1, 2023

Study Completion Date

March 1, 2023

Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
RADIATION

68Ga-DOTA-NT-20.3

In this study, all patients will receive one injection of 68Ga-DOTA-NT-20.3, a PET radiopharmaceutical selective for neurotensin receptor 1 (NTR-1). For the injection, subjects will receive a target dose of 2-4 MBq per kg of body weight as a bolus injection. 68Ga-DOTA-NT-20.3 injection will be followed by a 10 ml saline flush.

Trial Locations (1)

Unknown

Nanjing First Hospital, Nanjing

All Listed Sponsors
lead

Nanjing First Hospital, Nanjing Medical University

OTHER

NCT05048810 - Clinical Application of 68Ga-DOTA-NT-20.3 in the Early Diagnosis of Pancreatic Ductal Adenocarcinoma | Biotech Hunter | Biotech Hunter